ABBV Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 1.13% compared to AbbVie, Inc.'s net margin of 21.47%. AbbVie, Inc.'s return on equity of 144.3% beat Johnson & Johnson's return on equity of 33.27%.

AbbVie, Inc. has a consensus price target of $243.55, signalling upside risk potential of 5.78%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could fall by -1.36%. Given that AbbVie, Inc. has higher upside potential than Johnson & Johnson, analysts believe AbbVie, Inc. is more attractive than Johnson & Johnson.

AbbVie, Inc. has a beta of 0.358, which suggesting that the stock is 64.24% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

AbbVie, Inc. has a quarterly dividend of $1.64 per share corresponding to a yield of 2.85%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. AbbVie, Inc. pays 263.15% of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie, Inc.'s is not.

AbbVie, Inc. quarterly revenues are $15.8B, which are smaller than Johnson & Johnson quarterly revenues of $24B. AbbVie, Inc.'s net income of $178M is lower than Johnson & Johnson's net income of $5.2B. Notably, AbbVie, Inc.'s price-to-earnings ratio is 173.73x while Johnson & Johnson's PE ratio is 19.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie, Inc. is 6.84x versus 5.40x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 1.13% compared to AbbVie, Inc.'s net margin of 31.72%. AbbVie, Inc.'s return on equity of 144.3% beat Eli Lilly & Co.'s return on equity of 106.26%.

AbbVie, Inc. has a consensus price target of $243.55, signalling upside risk potential of 5.78%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,045.59 which suggests that it could grow by 1.16%. Given that AbbVie, Inc. has higher upside potential than Eli Lilly & Co., analysts believe AbbVie, Inc. is more attractive than Eli Lilly & Co..

AbbVie, Inc. has a beta of 0.358, which suggesting that the stock is 64.24% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

AbbVie, Inc. has a quarterly dividend of $1.64 per share corresponding to a yield of 2.85%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. AbbVie, Inc. pays 263.15% of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie, Inc.'s is not.

AbbVie, Inc. quarterly revenues are $15.8B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. AbbVie, Inc.'s net income of $178M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, AbbVie, Inc.'s price-to-earnings ratio is 173.73x while Eli Lilly & Co.'s PE ratio is 51.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie, Inc. is 6.84x versus 15.86x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 1.13% compared to AbbVie, Inc.'s net margin of 33.68%. AbbVie, Inc.'s return on equity of 144.3% beat Merck & Co., Inc.'s return on equity of 39.63%.

AbbVie, Inc. has a consensus price target of $243.55, signalling upside risk potential of 5.78%. On the other hand Merck & Co., Inc. has an analysts' consensus of $105.35 which suggests that it could grow by 3.01%. Given that AbbVie, Inc. has higher upside potential than Merck & Co., Inc., analysts believe AbbVie, Inc. is more attractive than Merck & Co., Inc..

AbbVie, Inc. has a beta of 0.358, which suggesting that the stock is 64.24% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

AbbVie, Inc. has a quarterly dividend of $1.64 per share corresponding to a yield of 2.85%. Merck & Co., Inc. offers a yield of 3.17% to investors and pays a quarterly dividend of $0.81 per share. AbbVie, Inc. pays 263.15% of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie, Inc.'s is not.

AbbVie, Inc. quarterly revenues are $15.8B, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. AbbVie, Inc.'s net income of $178M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, AbbVie, Inc.'s price-to-earnings ratio is 173.73x while Merck & Co., Inc.'s PE ratio is 13.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie, Inc. is 6.84x versus 4.03x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 1.13% compared to AbbVie, Inc.'s net margin of 21.32%. AbbVie, Inc.'s return on equity of 144.3% beat Pfizer Inc.'s return on equity of 10.84%.

AbbVie, Inc. has a consensus price target of $243.55, signalling upside risk potential of 5.78%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Pfizer Inc. has higher upside potential than AbbVie, Inc., analysts believe Pfizer Inc. is more attractive than AbbVie, Inc..

AbbVie, Inc. has a beta of 0.358, which suggesting that the stock is 64.24% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

AbbVie, Inc. has a quarterly dividend of $1.64 per share corresponding to a yield of 2.85%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. AbbVie, Inc. pays 263.15% of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

AbbVie, Inc. quarterly revenues are $15.8B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. AbbVie, Inc.'s net income of $178M is lower than Pfizer Inc.'s net income of $3.6B. Notably, AbbVie, Inc.'s price-to-earnings ratio is 173.73x while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie, Inc. is 6.84x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.